Sponsors › Innovent Biologics

Innovent Biologics

Every GLP‑1 and incretin trial, approval and scheduled result we hold for Innovent Biologics, drawn from ClinicalTrials.gov and Drugs@FDA.

Innovent Biologics is a commercial sponsor with 13 trials in the incretin class on file here, across 3 molecules. The programme is split between 4 early-stage trials and 9 in phase 3 or later. No approved FDA submission is recorded against this sponsor for these molecules, which is normal for a programme that has not reached the market. The next scheduled result is 2026-12-31.

Molecules

dulaglutide · mazdutide · semaglutide

Trials on file

13

Active trials

6

Results scheduled

3

Approved FDA submissions

0

Results due

Trials on file

All 13 incretin trials recorded for this sponsor, active first.